Natera, Inc. Stock News

Natera, Inc. ( NTRA ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 10:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. So last run of the day.

Natera, Inc. ( NTRA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Steve Chapman - CEO & Director Mike Brophy - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division So I am going to go ahead and kick it off. I'm Tycho Peterson from the ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its employees contributed more than 1,500 volunteer hours during the company's fourth annual Volunteer Month. This initiative takes place each October and is organized by Natera Nurtures, the company's employee resource group dedicated to community service a...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera's oncology testing portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platfor...

Natera, Inc. ( NTRA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Conference Call Participants Noah Kava - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Da...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenu...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in single-gene noninvasive prenatal testing (sgNIPT). Building on the success of the initial Fetal Focus 5-gene test, launched in August, the new expanded panel will launch...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information Event: Natera's Third...